IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immuneering Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.66+0.07 (+1.95%)
Close on Oct 19, 2026
- Market cap
- $236.79M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 117.5% | -43.1% | |
| Return on assets | – | – | -39.4% | |
| Current ratio | – | 16.73 | 17.50 | |
| Capex to revenue | – | 2.3% | – | |
| Diluted shares | – | 5M | 44M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Immuneering generated $224.26M from operations and spent $1.37M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$224.26M
Used
$1.37M
Capital expenditure$1.37M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-15937.3%
×Asset turnover0.00×
×Equity multiplier1.09×
=Return on equity, FY2022-38.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -15937.3% | 0.00× | 1.09× | -38.0% |
| FY2021 | -1612.3% | 0.02× | 1.54× | -50.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$56.02M
- Cash generatingOperating cash flow above zero-$45.34M
- Return on assets improvedROA up on the prior year-59.5% → -106.3%
- Earnings backed by cashOperating cash flow above net income-$45.34M vs -$56.02M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.28 → 17.50
- No dilutionShare count did not rise30M → 44M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –